L. Paz-Ares

发表

Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial.

E. Felip, F. de Marinis, M. Taron, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Concomitant Actionable Mutations and Overall Survival (OS) in Egfr-Mutant Non-Small-Cell Lung Cancer (NSCLC) Patients (P) Included in The Eurtac Trial: EGFR L858R, EGFR T790M, TP53 R273H and EML4-ALK (V3)

C. Mermel, E. Felip, J. Bosch-Barrera, 2012 .

Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platform

T. Gorlia, A. Dingemans, E. Felip, 2022, Scientific Reports.

First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours

J. Tabernero, T. Yap, D. Olmos, 2012, British Journal of Cancer.

Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM)

J. Baselga, J. Albanell, R. Rosell, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

CMV front-line chemotherapy in transitional bladder carcinoma.

F. Rivera, H. Cortés-Funes, J. Passás, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Definition of synchronous oligo-metastatic non-small cell lung cancer - a consensus report.

C. Dooms, N. Girard, H. Gietema, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Systemic chemotherapy in the management of malignant peritoneal mesothelioma.

R. García-Carbonero, L. Paz-Ares, 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP).

C. Swanton, U. Dafni, D. de Ruysscher, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety and efficacy of pralsetinib in RET fusion-positive non-small cell lung cancer including as first-line therapy: update from the ARROW trial.

Y. Houvras, A. Mansfield, J. Mazières, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.

K. O'Byrne, T. Mok, E. Tan, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Fluorouracil-Based Chemotherapy in Patients with Gastrointestinal Malignancies: Influence of Nutritional Folate Status on Toxicity

R. García-Carbonero, L. Paz-Ares, C. García-Lacalle, 2007, Journal of chemotherapy.

Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small cell lung cancer: a pooled analysis.

K. O'Byrne, S. Ramalingam, M. Hellmann, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC

J. Lunceford, M. Ayers, B. Halmos, 2022, JTO clinical and research reports.

Lung adenocarcinoma in the era of targeted therapies: histological classification, sample prioritization, and predictive biomarkers

M. Hidalgo, F. López-Ríos, B. Angulo, 2013, Clinical and Translational Oncology.

Biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

F. López-Ríos, E. Felip, L. Paz-Ares, 2015, Clinical and Translational Oncology.

LBA10 Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study

A. Dingemans, J. Mazières, M. Schuler, 2022, Annals of Oncology.

ESMO expert consensus statements on the management of EGFR mutant Non-Small Cell Lung Cancer.

P. Jänne, I. Wistuba, L. Sequist, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS–RAF Mutations

J. Larkin, M. Venturi, J. Schellens, 2014, Clinical Cancer Research.

Entrectinib in NTRK fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of patients (pts) enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001.

J. Krauss, R. Doebele, J. Wolf, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

A cost‐effectiveness analysis of sunitinib in patients with metastatic renal cell carcinoma intolerant to or experiencing disease progression on immunotherapy: perspective of the Spanish National Health System

E. Grande, S. Díaz, J. G. del Muro, 2010, Journal of clinical pharmacy and therapeutics.

Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN

H. Mann, M. Hochmair, L. Havel, 2022, ESMO open.

Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study

W. Mason, J. Machiels, B. Melichar, 2022, ESMO open.

N. Girard, A. Stenzinger, C. Swanton, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

LBA49 CANOPY-A: Phase III study of canakinumab (CAN) as adjuvant therapy in patients (pts) with completely resected non-small cell lung cancer (NSCLC)

A. Ardizzoni, C. Bossen, F. Barlesi, 2022, Annals of Oncology.

Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial

S. Senan, Y. Wu, H. Mann, 2022, ESMO open.

Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials.

G. Scagliotti, C. Gridelli, F. de Marinis, 2014, Lung cancer.

VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study

U. Dafni, R. Stahel, M. Mauer, 2022, Annals of Oncology.

108MO Safety and efficacy outcomes with durvalumab after sequential chemoradiotherapy (sCRT) in stage III, unresectable NSCLC (PACIFIC-6)

J. Mazières, A. Delmonte, M. Reck, 2022, Annals of Oncology.

930MO PD-L1 expression and outcomes of pembrolizumab and placebo in completely resected stage IB-IIIA NSCLC: Subgroup analysis of PEARLS/KEYNOTE-091

U. Dafni, R. Stahel, M. Mauer, 2022, Annals of Oncology.

4O Nivolumab (NIVO) + ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced NSCLC (aNSCLC) in CheckMate 227 part 1: Efficacy by KRAS, STK11, and KEAP1 mutation status

K. O'Byrne, S. Ramalingam, M. Hellmann, 2021, Annals of Oncology.

1550TiP Phase II, multicenter, randomized, open-label study of DS-7300 in patients (pts) with pre-treated extensive-stage small cell lung cancer (ES-SCLC)

C. Rudin, C. Hann, L. Paz-Ares, 2022, Annals of Oncology.

975P Trastuzumab deruxtecan in patients (pts) with HER2-overexpressing (HER2-OE) metastatic non-small cell lung cancer (NSCLC): Results from the DESTINY-Lung01 trial

P. Jänne, E. Felip, D. Planchard, 2022, Annals of Oncology.

EP14.01-015 IMforte: A Phase III Study of Lurbinectedin and Atezolizumab Versus Atezolizumab as Maintenance Therapy in ES-SCLC

H. Borghaei, M. Reck, V. Cuchelkar, 2022, Journal of Thoracic Oncology.

Social value of a quality-adjusted life year (QALY) in Spain: the point of view of oncologists

A. Carrato, R. López-López, E. Díaz-Rubio, 2014, Clinical and Translational Oncology.

ERCC1 mRNA-based randomized phase III trial of docetaxel (doc) doublets with cisplatin (cis) or gemcitabine (gem) in stage IV non-small-cell lung cancer (NSCLC) patients (p)

E. Felip, R. Rosell, N. Viñolas, 2005 .

Novel carcinoembryonic antigen T-cell bispecific (CEA-TCB) antibody: Preliminary clinical data as a single agent and in combination with atezolizumab in patients with metastatic colorectal cancer (mCRC).

J. Albanell, J. Tabernero, H. Hurwitz, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

362P Phase Ia study to evaluate GDC-6036 monotherapy in patients with colorectal cancer (CRC) with KRAS G12C mutation

M. Krebs, A. Sacher, M. D. de Miguel, 2022, Annals of Oncology.

Impact of the COVID-19 pandemic on the care of cancer patients in Spain

X. Matías-Guiu, Á. Rodríguez-Lescure, J. C. de la Torre-Montero, 2021, ESMO Open.

1010P Assessment of early resistance mechanisms to first-line osimertinib in EGFR-mutant NSCLC using spatial transcriptomics

J. Zugazagoitia, D. Isla, J. M. Sánchez Torres, 2022, Annals of Oncology.

Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results

M. Nishio, M. Reck, E. Garon, 2023, ESMO open.

122MO Nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment (tx) for patients (pts) with advanced NSCLC (aNSCLC) and baseline (BL) brain metastases (mets): Intracranial and systemic outcomes from CheckMate 227 Part 1

K. O'Byrne, M. Hellmann, H. Borghaei, 2021, Annals of Oncology.

Efficacy and safety evaluation based on time from completion of radiotherapy to randomization with durvalumab or placebo in pts from PACIFIC.

C. Faivre-Finn, S. Senan, D. Raben, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS–RAF Mutations

J. Larkin, M. Venturi, J. Schellens, 2014, Clinical Cancer Research.

Pemetrexed plus cisplatin (P+Cis) or pemetrexed plus carboplatin (P+Cb) for chemonaive patients (pts) with malignant pleural mesothelioma (MPM): Results of the International Expanded Access Program (EAP)

K. Nackaerts, R. Stahel, A. Santoro, 2007 .

P2.04-002 CASPIAN: Phase 3 Study of First-Line Durvalumab ± Tremelimumab + Platinum-Based Chemotherapy vs Chemotherapy Alone in ED-SCLC

Haiyi Jiang, P. Dennis, Y. Huang, 2017 .

509MO Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01

H. Hayashi, L. Paz-Ares, H. Zebger-Gong, 2023, Annals of Oncology.

518MO TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)

E. Felip, L. Paz-Ares, H. Zebger-Gong, 2023, Annals of Oncology.